Strasbourg, France, February 2018 – French-based Medtech company Defymed confirms
its global position. Recognized by its peers for the development of two innovative medical
devices – ExOlin®, an insulin delivery device, and MailPan®, a bioartificial pancreas – the
company intends to strengthen its position as a worldwide leader in innovative
physiological treatments of diabetes and chronic diseases.
To support the entry of ExOlin® into the clinical phase and the scientific development of
MailPan®, Defymed is seeking 10 million euros in 2018, backed by specialist health and
Medtech funds. In the spirit of open innovation, Defymed also intends to draw on new
partnerships in Asia, Europe, and the USA.
For more info, please check the related Press Release.